Ultrasound Guided Fine-Needle Aspiration Biopsy Proves 100% Accurate in 166 Women

Publication
Article
OncologyONCOLOGY Vol 9 No 6
Volume 9
Issue 6

A study of 166 women with suspicious mammograms who underwent ultrasound-guided fine-needle aspiration cytology (USFNAC) showed the technique to be 100% accurate in diagnosing cancers, reported Dr. Thomas G. Frazier at the annual

A study of 166 women with suspicious mammograms who underwentultrasound-guided fine-needle aspiration cytology (USFNAC) showedthe technique to be 100% accurate in diagnosing cancers, reportedDr. Thomas G. Frazier at the annual meeting of the American RadiumSociety, held in Paris, France. This number is based on 3-monthfollow-up of the patients, said Dr. Frazier, who is Senior AttendingSurgeon at the Bryn Mawr Hospital in Bryn Mawr, Pennsylvania,

"We found 17 early cancers in our study (none could be felt),"said Dr. Frazier, who is also Clinical Professor of Surgery atthe Medical College of Pennsylvania. "In our study, the costto diagnose each cancer was $4,667 when USFNAC was used. Thiscompares to $52,505 per cancer diagnosed for standard biopsy procedures.That's more than a 91% savings," he commented.

"We looked at the costs of biopsy alone by averaging thecosts of five patients and found that standard biopsies cost about$5,377. This compares to USFNAC, which costs only $478 per procedure,"he said.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.